Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.
Developer of an artificial intelligence-based fetal ultrasound software intended to analyze and diagnose congenital malformations. The company's software combines the patient's medical history, genetic and biological data, and ultrasound semiology to assist physicians on the path to the right diagnosis and assists sonographers during prenatal screening scans, enabling healthcare practitioners to receive crucial support in conducting fetal ultrasound and mothers to take care of themselves and their children.
Diabeloop SAS is a medical device company based in Grenoble, France, that specializes in developing an electronic artificial pancreas for individuals with Type 1 diabetes. Founded in 2015, the company's innovative system comprises a continuous glucose sensor that monitors blood sugar levels and a smartphone application that communicates with a connected insulin pump to administer the optimal insulin dosage automatically. This closed-loop system aims to minimize the risk of hypoglycemia and related complications, thereby improving the quality of life for patients. By integrating advanced technology and artificial intelligence, Diabeloop seeks to streamline diabetes management, reducing the mental burden on users and allowing them to lead more uninterrupted lives.
Implicity is a developer of a remote monitoring platform that enables the smart monitoring of patients with connected pacemakers and defibrillators. The platform utilizes artificial intelligence to sort and summarize patient data, assessing the criticality of alerts based on each patient's medical context. This innovative approach allows cardiologists and healthcare professionals to automate the remote monitoring process, consolidating patients' telepulse information into a single platform. By enhancing the efficiency of monitoring, Implicity aims to support hospital teams in delivering optimal quality care to their patients.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.
Susu is a health tech company focused on providing accessible and affordable healthcare services to families in the African diaspora. The company offers a comprehensive range of services, including preventive care, medical treatments, chronic disease management, and authentic medications. By delivering health bundle services through its platform, Susu aims to facilitate long-term health support for patients, ensuring effective monitoring of various health conditions such as pregnancy and chronic diseases. This approach enables individuals to access quality healthcare services and insurance, promoting overall well-being within the communities it serves.
Developer a biotechnology platform intended to improve the quality of life of patients. The company's platform specializes in developing an alternate method for the depletion of senescent cells in age-related pathologies using immunotherapy with cancer therapy and senescence, enabling patients to have proper health and treatment.
Depixus SAS is a biotechnology company based in Paris, France, focused on the development of advanced technology for extracting genetic and epigenetic information from single molecules of DNA and RNA. Its main product, SIMDEQ™ (SIngle-molecule Magnetic DEtection and Quantification), enables fast, accurate, and cost-effective analysis of genomes and epigenetic modifications. Initially developed at École Normale Supérieure by prominent researchers, SIMDEQ™ allows for the identification, counting, full sequencing, and epityping of millions of individual DNA molecules with high precision. The technology has broad applications in the life sciences and medical fields, facilitating real-time analysis of biomolecular interactions and supporting researchers in uncovering new biological pathways, understanding disease mechanisms, and advancing precision medicine. With substantial validation completed, Depixus is moving towards platform optimization and commercialization to enhance its offerings in these critical areas.
KINVENT is actively involved in the fields of physical rehabilitation and sports biomechanics producing innovative measuring and training devices for the facilitation of every day and athletic movements. Our strengths at KINVENT is that we can think and produce solutions to any challenge of sports biomechanics and physical rehabilitation. Triangular force plates for visual feedback balance training, sensors for continuous 3D kinematic analysis in the water, force sensors for kite surf, accelerometers for rowing and sailing, are some of our on demand products. If you are looking for excellence in hardware and software solutions for your work... work with us. Our KFORCE solution is a range of torque measuring instruments for human strength, balance and motion. This system consists of six instruments with high-precision measuring equipment, which concentrate all the know-how of K-INVENT. The display of the data recorded by the device sensors is transcribed by the KFORCE software, installed on any iOS or Android terminal. This accessory capable of reading and re-transcribing the information given by all dynamometers of the entire range is usable on smartphones or tablets with Android and IOS operating system
Echoliv is a medical technology company specializing in artificial intelligence solutions for abdominal ultrasound. The company develops software designed to assist radiologists and hepatologists in early-stage screening for hepatocellular carcinoma, the most common type of liver cancer. Echoliv's flagship product, Ultraliv, employs advanced algorithms to identify nodules that may be overlooked by practitioners, enhancing diagnostic accuracy and improving patient care. By integrating AI into the ultrasound process, Echoliv aims to support healthcare professionals in delivering timely and effective treatment for liver cancer.
Developer of a tele-expertise platform designed to facilitate phone-based medical verification for patients eligible for health insurance facilities. The company's platform allows medical institutions or private physicians to secure and value informal opinions, strengthen the links between first and second recourse, centralize and promote requests from correspondents, and discover and contact doctors and organizations, enabling clients to improve, secure, and enhance the opinions exchanged and automate administrative tasks.
Arkhn is a platform specialist in healthcare data interoperability. Arkhn tackles the issue of accessing healthcare data.
OncoDiag is a French biotechnology company located in Normandy, dedicated to creating non-invasive diagnostic tests aimed at the early detection of cancers. Its flagship product, the Urotest, is a urine test approved for the diagnosis and monitoring of bladder cancer. In addition to the Urotest, OncoDiag is developing Colodiag, a test focused on the early identification of colorectal cancer, and other diagnostic tools, including a tissue-based test for predicting non-evolutive localized prostate cancer. Through its innovative testing kits, OncoDiag aims to enhance cancer diagnostics, allowing healthcare professionals to provide timely and effective patient care.
Omini is a company that specializes in the development of portable and multipurpose bio-sensing devices for blood tests, catering primarily to general practitioners. Established in 2019 and headquartered in Saint Mandé, France, Omini addresses a critical need in medical decision-making, as 70% of such decisions rely on clinical chemistry and assays like blood tests, which often require hours to days to yield results. The company’s innovative devices utilize multiplex electrochemical biosensor technology to simultaneously identify, analyze, and monitor multiple target biomarkers in real-time, allowing for quicker and more informed medical decisions. This technology not only facilitates decentralized testing and at-home monitoring for patients with chronic conditions but also aims to alleviate pressure on healthcare systems by providing affordable and immediate testing solutions.
Provider of consulting services focused on information systems security, digital strategy and project management for health organizations. The company offers to build patient and user experience, taking advantage of digital innovation, support and facilitating professional practice catering to the health sector to reconcile economic, ethical and societal challenges.
Grapheal introduces digital biosensing technology into embedded systems for on-site diagnostics and remote patient monitoring. Current applications are wound care digital assistant for improving the follow-up of difficult to heal wounds.
Braintale develops and distributes accessible and effective diagnosis and prognosis tools for brain injured patients.
Medaviz is a online platform which provides medical advice to bring patients and doctors into immediate contact.
Withings is a developer of digital health and wellness devices aimed at empowering individuals to make informed health decisions. The company offers a diverse range of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers, hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings provides medically accurate devices for monitoring blood pressure and temperature, allowing users to effectively track their health progress. These products facilitate data sharing with healthcare professionals, promoting a collaborative approach to personal health management.
Honing Biosciences SAS, a bio-therapeutics company, develops and improves cell-based therapies to treat cancer and other chronic diseases. It offers molecular CellTuneTM technology that allows to develop new classes of tunable cell therapeutics to control the dynamic delivery of proteins in patients. The company offers therapies, such as CAR-T (chimeric antigen receptor T) cells therapy to kill cancer cells and Checkpoint inhibitors, a technology allowing to select small antibodies (nanobodies) based on proprietary scaffold, which they can deliver intracellularly. Its technology regulates protein expression at the cell surface or secretion of enzymes, cytokines, antibodies, and adapting the delivery of therapeutic proteins to clinical evolutions. Honing Biosciences SAS was incorporated in 2018 and is based in Paris, France.
Dianosic SAS is a healthcare organization based in Strasbourg, France, founded in 2017. The company specializes in developing innovative medical devices for Ear, Nose, and Throat (ENT) conditions. Its flagship product, the CAVI-T, is an asymmetrical intranasal balloon designed to manage spontaneous or postoperative bleeding through low-pressure compression, tailored to the unique anatomy of the nasal cavity. This device also features an active balloon that minimizes biofilm formation, targets specific bacteria, and promotes healing. Additionally, Dianosic is developing an Active Resorbable Intranasal Scaffold device aimed at treating chronic sinusitis in patients who do not respond to conventional drug therapies. These advancements enable healthcare professionals to monitor patients remotely, enhancing post-operative care and overall treatment efficacy.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
Deeplink-Medical is the answer to the real needs of the field apprehended by the founding medical team and the inadequacy of available telemedicine IT solutions. The design of innovative tools led by an experienced medical team, coupled with a framework of practices (support, training, medical protocol, activity monitoring) ensure the success of a telemedicine project and the optimization of the management patients.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
SeqOne S.A.S. is a company based in Montpellier, France, that specializes in developing genomic data analysis software for the healthcare industry. Founded in 2017, SeqOne's platform offers end-to-end management of next-generation sequencing (NGS) and bioinformatics data, providing advanced tools for analyzing complex genomic information. The software is designed to deliver medically actionable results across various areas, including oncology, hematological diseases, rare diseases, genetic screening, and hereditary conditions. By addressing the challenges associated with analyzing rich genomic data, SeqOne aims to enhance the accessibility and effectiveness of genomic medicine, thereby facilitating improved treatment options for patients. The company serves both private and public healthcare sectors, contributing to the ongoing transformation of healthcare through the integration of genomic insights.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
SuperSonic Imagine SA operates as a medical technology company. It designs, develops, and markets Aixplorer, an ultrasound system. It has developed a technology that offers practitioners and patients a breakthrough in the diagnosis and follow up of breast, prostate, and thyroid cancers, as well as liver diseases. The company’s products include Aixplorer, an ultrasound system that renders images with exceptional definition, contrast, and resolution. It operates primarily in China, the United States, and France. The company was founded in 2005 and is headquartered in Aix-en-Provence, France. SuperSonic Imagine SA is a subsidiary of Hologic Hub Ltd.
Happytal, SAS offers concierge services to hospitals in France. Its services include providing a hairdresser in the room, a beautician, to receive the newspaper, and to offer a basket of fruits and meals. The company was founded in 2013 and is based in Vanves, France.
C4Diagnostics is a company based in Marseille, France, that specializes in the development and commercialization of in vitro diagnostic (IVD) kits. Founded in 2017, the company focuses on creating technology that enables the detection, counting, and concentration of culturable microorganisms in clinical microbiology. Its innovative approach is designed to enhance the speed and sensitivity of diagnostic tests, particularly for urinary tract infections. By providing hospitals and laboratories with advanced tools for culture-based testing and specific fluorescence, C4Diagnostics aims to improve diagnostic accuracy and efficiency in medical settings.
Doctoconsult SAS is a French company that specializes in providing online healthcare consultation services, focusing primarily on mental health. Founded in 2016 and headquartered in Fresnes, France, it offers support for a range of issues including depressive states, sleep disorders, anxiety, phobias, eating disorders, addictions, and family problems. Notably, it is recognized as the first video consultation service dedicated to psychiatrists in France. The company has recently launched an innovative app developed in collaboration with key opinion leaders and researchers aimed at assisting patients with mental disorders.
Discngine provides scientific computing consulting services & solutions for Life Sciences Research. They are specialized in the integration of scientific software like BIOVIA - Accelrys Pipeline Pilot, Chemaxon, CambridgeSoft and industry standards like Oracle database or Tibco Spotfire.
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
BioSerenity souhaite aider la communauté scientifique à mieux comprendre l'épilepsie pour mieux la soigner. Une fois anonymisées et privées de tout lien avec le patient, les données recueillies seront mise à disposition des chercheurs de l'Institut du Cerveau et de la Moelle épinière (ICM). C'est un pas décisif pour faire avancer la recherche sur l'épilepsie et améliorer le futur du diagnostic
TxCell S.A. is a biotechnology company based in Valbonne, France, specializing in cellular immunotherapies that leverage regulatory T cells (Tregs) to address severe chronic inflammatory diseases, autoimmunity, and transplantation challenges. The company develops innovative therapies using Tregs engineered with chimeric antigen receptors (CARs) for various conditions, including TX200, aimed at preventing graft rejection in solid organ transplants, and treatments for autoimmune diseases such as bullous pemphigoid and multiple sclerosis. TxCell is also advancing Ovasave, a therapy for refractory Crohn's disease, having completed an initial study with positive outcomes and planning further clinical trials. The company collaborates with prominent research institutions, including the Lübeck Institute of Experimental Dermatology and the University of British Columbia, to enhance its research and development efforts. TxCell operates as a subsidiary of Sangamo Therapeutics, Inc., continuing its focus on innovative immunotherapy solutions.
Doctolib is an online booking platform and management software provider based in Paris, France, that serves the healthcare sector across Europe. Established in 2013, the platform connects patients with healthcare practitioners, facilitating the scheduling of appointments with ease. With 25 million monthly visitors, it supports 65,000 health practitioners in over 1,300 facilities, offering a comprehensive service that enhances appointment management, reduces no-show rates, and attracts new patients. For patients, Doctolib provides a free service that allows them to find nearby doctors or dentists and book appointments 24/7 in just a few clicks. The platform aims to streamline access to healthcare services for both practitioners and patients, improving overall efficiency in the healthcare system.
H4D is a French company founded in 2008 that specializes in designing and developing telehealth booths, particularly through its product, the Consult Station. This device enables remote medical consultations by allowing users to conduct self-check-ups and facilitating the monitoring of both acute and chronic diseases. H4D aims to enhance access to healthcare, addressing geographic and social isolation while promoting preventative medicine. The company serves diverse clients, including local authorities, senior care facilities, hospitals, corporations, and insurance providers, ensuring that its health solutions are integrated into broader healthcare strategies. H4D is committed to maintaining effective communication with local healthcare stakeholders to support its health programs and enhance overall accessibility to medical care.
Private Equity Round in 2016
MédiPôle Partenaires is a group of private clinics whose competence is particularly recognized in the fields of Medicine of Obstetric Surgery (MCO), Continuing Care and Rehabilitation (SSR) and Home Hospitalization (HAD).
Cardiologs Technologies SAS is a medical technology company based in Paris, France, founded in 2014. It specializes in the development of a cloud-based platform for electrocardiogram (ECG) analysis that enhances the management of cardiac patients. The Cardiologs ECG Analysis Platform leverages medical-grade artificial intelligence and deep learning technology to assist physicians in screening for conditions such as atrial fibrillation and other arrhythmias. The platform analyzes long-term ambulatory ECG recordings and recognizes patterns in digital ECG signals, providing clinicians with critical insights for interpreting heart disorders. Cardiologs aims to democratize expert cardiac care by making advanced diagnostics accessible to healthcare practitioners globally. Its extensive database of over 1,450,000 recordings, supported by clinical publications, underpins its commitment to delivering high-quality cardiac diagnostics.
Magnisense conçoit, développe et commercialise des tests de diagnostic d'urgence pour les maladies cardio-vasculaires à partir de sa technologie MIAtek® et de son instrument de diagnostic propriétaires
Poxel S.A. is a biopharmaceutical company based in Lyon, France, focused on developing innovative treatments for metabolic diseases, primarily type 2 diabetes and non-alcoholic steatohepatitis (NASH). Founded in 2009 as a spin-off from Merck Serono, Poxel is advancing its lead product, Imeglimin, through Phase III clinical trials; this oral anti-diabetic candidate targets organ functions affected by diabetes, such as the pancreas, liver, and muscles. The company is also developing PXL770, currently in Phase IIa trials, which activates the adenosine monophosphate-activated protein kinase (AMPK) to manage energy metabolism, and PXL065, a mitochondrial pyruvate carrier inhibitor in Phase I trials for NASH. Additionally, Poxel has a licensing agreement with Enyo Pharma for the development of PXL007, an FXR agonist in Phase I studies for hepatitis B and NASH. The company’s pipeline reflects its commitment to addressing critical targets in cellular energy regulation, which are vital for treating metabolic disorders.
Voluntis, Inc. develops digital therapeutic solutions for diabetes, oncology, and other therapeutic areas. It offers Insulia, a prescription-only medical device that provides type 2 diabetes patients with insulin dose recommendations and educational coaching messages based on blood glucose values and other diabetes-related data; and Diabeo, a digital solution for type 1 and type 2 patients treated on a basal-bolus insulin regimen, which suggests insulin dosage, through algorithmic calculations that are specific to the patient and based on their particular doses. Voluntis, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Skuldtech is specialized in the discovery of new Biomarkers and the development of Diagnostics focused on personalized medicine applications. This expertise enables the company to provide genomic, pharmacogenomic and transcriptomic services, as well as innovative diagnostics associated with new treatments, especially in cancer, neurodegenerative and infectious diseases.
Withings is a developer of digital health and wellness devices aimed at empowering individuals to make informed health decisions. The company offers a diverse range of products, including smart scales that help users achieve fitness and weight goals, stylish activity trackers, hybrid smartwatches, and an advanced sleep-tracking mat. Additionally, Withings provides medically accurate devices for monitoring blood pressure and temperature, allowing users to effectively track their health progress. These products facilitate data sharing with healthcare professionals, promoting a collaborative approach to personal health management.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.
Domain Therapeutics SA is a biopharmaceutical company based in Illkirch-Graffenstaden, France, focused on the discovery and early development of therapeutic drugs targeting G Protein-Coupled Receptors (GPCRs), which are key drug targets in various diseases. The company specializes in developing treatments for Central Nervous System (CNS) disorders and cancer. Utilizing its proprietary DTect-All technology, Domain Therapeutics identifies both orthosteric and allosteric ligands, including Silent Allosteric Modulators (SAMs), which are not discoverable through conventional methods. This innovative approach allows the company to address challenging GPCRs, including orphan and peptidic receptors. Founded in 2001, the company was previously known as Faust Pharmaceuticals SA before rebranding in December 2008.